Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells.
J Med Virol
; 93(3): 1403-1408, 2021 03.
Article
in English
| MEDLINE | ID: covidwho-1196439
ABSTRACT
Drug repositioning represents an effective way to control the current COVID-19 pandemic. Previously, we identified 24 FDA-approved drugs which exhibited substantial antiviral effect against severe acute respiratory syndrome coronavirus 2 in Vero cells. Since antiviral efficacy could be altered in different cell lines, we developed an antiviral screening assay with human lung cells, which is more appropriate than Vero cell. The comparative analysis of antiviral activities revealed that nafamostat is the most potent drug in human lung cells (IC50 = 0.0022 µM).
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
SARS-CoV-2
/
Guanidines
Limits:
Animals
/
Humans
Country/Region as subject:
North America
Language:
English
Journal:
J Med Virol
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS